Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908495 | 0.89 | ALDH1A1 (0.38) | EPHX2NR1H4ALDH1A1TSHRTDP1 | |
| SCHEMBL23039308 | 0.83 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1CYP3A4ALOX15 | |
| SCHEMBL6867541 | 0.81 | ALDH1A1 (0.41) | NR1H4ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL6867546 | 0.81 | ALDH1A1 (0.41) | NR1H4ALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL6515361 | 0.79 | TP53 (0.37) | EPHX2NR1H4ALDH1A1TSHRTDP1 | |
| SCHEMBL543918 | 0.79 | TSHR (0.51) | ALDH1A1TSHRTDP1CYP3A4ALOX15 | |
| SCHEMBL4960492 | 0.78 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1CYP3A4ALOX15 | |
| SCHEMBL18306112 | 0.78 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1CYP3A4ALOX15 | |
| SCHEMBL9671806 | 0.78 | TSHR (0.44) | ALDH1A1TSHRTDP1CYP3A4ALOX15 | |
| SCHEMBL7077212 | 0.78 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| EP-3762393-B1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3601297-B1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | AMGEN INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20190016736-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3424931-A2 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | Amgen, Inc (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3186259-B1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10100063-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-11 | — | — | US | disclosed |
| WO-2018183418-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2017147410-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | EPHX2 4618/4885NR1H4 4577/4885ALDH1A1 1891/4885 |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | EPHX2 4520/4885NR1H4 4545/4885ALDH1A1 1575/4885 |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | EPHX2 4512/4885NR1H4 4611/4885ALDH1A1 1431/4885 |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | EPHX2 4512/4885NR1H4 4611/4885ALDH1A1 1431/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | EPHX2 4512/4885NR1H4 4611/4885ALDH1A1 1431/4885 |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | EPHX2 4618/4885NR1H4 4577/4885ALDH1A1 1891/4885 |
| US-10100063-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | EPHX2 4618/4885NR1H4 4577/4885ALDH1A1 1891/4885 |
| US-20190016736-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | EPHX2 4512/4885NR1H4 4611/4885ALDH1A1 1431/4885 |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | EPHX2 4618/4885NR1H4 4577/4885ALDH1A1 1891/4885 |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | MCL1, BCL2A1, BCLAF1 | EPHX2 4106/4885NR1H4 2053/4885ALDH1A1 59/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | EPHX2 4618/4885NR1H4 4577/4885ALDH1A1 1891/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | EPHX2 4618/4885NR1H4 4577/4885ALDH1A1 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.